VECTION TECH S/ADR by VECTION TECHNOLOGIES LTD Stock (OTC: VCTNY)

Latest news for VECTION TECH S/ADR by VECTION TECHNOLOGIES LTD (OTC:VCTNY) Stock

VECTION TECH S/ADR by VECTION TECHNOLOGIES LTD

MGM Resorts International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MGM#NYSE">MGM</a>) reported its second-quarter financial results Wednesday. Here's a look at the <a href="https://www.benzinga.com/pressreleases/24/07/n40081327/mgm-resorts-international-reports-second-quarter-2024-financial-and-operating-results">details from the report. </a>
The Details: MGM Resorts reported quarterly earnings of 86 cents per share, which beat the analyst consensus estimate of 62 cents by 38.71%.
Quarterly sales clocked in at $4.3 billion, which beat the analyst consensus estimate of $4.22 billion and represents a 9.08% increase from the same period last year.
Las Vegas strip resorts net revenues were $2.2 billion, an increase of 3% year-over-year, due primarily to an increase in rooms revenue, driven by an increase in ADR, and an increase in catering and banquets revenue. 
China MGM net revenues were $1 billion in the current quarter, an increase of 37% year-over-year. The current quarter was positively affected by the continued ramp-up of operations after the removal of COVID-19-related travel and entry restrictions in the first quarter of 2023. Regional operations net revenues were $927 million in the current quarter and flat compared to the prior-year quarter.
Read Also: <a href="https://www.benzinga.com/news/earnings/24/07/40076709/whats-going-on-with-sofi-stock-after-earnings">What&#8217;s Going On With SoFi Stock After Earnings?</a>
&#8220;MGM Resorts continued to drive positive financial results and solid growth in the second quarter, with record MGM China Adjusted Property EBITDAR and further growth in Las Vegas where our Marriott relationship continues to exceed expectations and our meetings and convention business continues to strengthen thanks to our recently completed remodel of Mandalay Bay,&#8221; said Bill Hornbuckle, CEO of MGM Resorts International.
MGM Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, MGM Resorts International shares are down 4% after-hours at $41.25 at the time of publication Wednesday.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/07/40051630/match-group-stock-climbs-on-strong-q2-results-hinge-revenue-up-48">Match Group Stock Climbs On Strong Q2 Results, Hinge Revenue Up 48%</a></li>
</ul>
Image: Csaba Nagy from Pixabay

Earnings

News

After-Hours Center

Movers

MGM Resorts Reports Better-Than-Expected Q2 Results, Record Net Revenues

Guidance

Carriage Services Sees 2024 Adj. EPS $2.30-$2.40 vs $2.27 Est., Total Revenue $390M-$400M vs $386.1M Est.

Magnachip Now Expects FY24 Consolidated Revenue Flattish-To-Slightly Down, Compared To Prior Expectation Of Flat-To-Up-slightly Y/Y

Braemar Hotels &amp; Resorts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHR#NYSE">BHR</a>) reported quarterly earnings of $0.10 per share which missed the analyst consensus estimate of $0.14 by 28.57 percent. This is a 50 percent decrease over earnings of $0.20 per share from the same period last year. The company reported quarterly sales of $187.587 million which beat the analyst consensus estimate of $185.095 million by 1.35 percent. This is a 0.47 percent increase over sales of $186.707 million the same period last year.

Earnings Beats

Earnings Misses

Braemar Hotels & Resorts Q2 2024 FFO $0.10 Misses $0.14 Estimate, Sales $187.587M Beat $185.095M Estimate

LRCX

Lam Research Extends Leadership In 3D NAND Flash Memory Etching With Introduction Of Lam Cryo 3.0; New Technology Enhances Etch Capabilities For Future High-Capacity Memory Demand Driven By AI Proliferation

Magnachip Expects Q3 Consolidated Revenue Of $61.5M - $66.5M, Est $62.5M

LUNG

Pulmonx Continues To Expect FY24 Revenue $81M-$84M

MYR Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYRG#NASDAQ">MYRG</a>) reported quarterly losses of $(0.91) per share which missed the analyst consensus estimate of $1.13 by 180.53 percent. The company reported quarterly sales of $828.890 million which missed the analyst consensus estimate of $876.070 million by 5.39 percent. This is a 6.72 percent decrease over sales of $888.616 million the same period last year.

MYRG

MYR Group Q2 2024 GAAP EPS $(0.91) Misses $1.13 Estimate, Sales $828.890M Miss $876.070M Estimate

WIIM

Magnachip Semiconductor shares are trading higher after the company reported better-than-expected Q2 financial results.

Bogota Finl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSBK#NASDAQ">BSBK</a>) reported quarterly losses of $(0.03) per share. This is a 142.86 percent decrease over earnings of $0.07 per share from the same period last year.

BSBK

Bogota Finl Q2 EPS $(0.03) Down From $0.07 YoY

KXIN

Kaixin Holdings shares are trading higher after the company announced it received a non-compliance notification from the Nasdaq.

Jianzhi Education Technology Receives Nasdaq Non-Compliance Notice For Minimum Market Value Requirement; Company Fails To Meet $5M Market Value Rule Over 30 Consecutive Business Days

NTGR

NETGEAR Sees Q3 Net Revenue $160M-$175M

IMRX

Immuneering shares are trading higher after the company announced that IMM-1-104  was granted Fast Track designation from the FDA.

APA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APA#NASDAQ">APA</a>) reported quarterly earnings of $1.17 per share which beat the analyst consensus estimate of $1.08 by 8.33 percent. This is a 37.65 percent increase over earnings of $0.85 per share from the same period last year. The company reported quarterly sales of $2.79 billion which beat the analyst consensus estimate of $2.37 billion by 17.81 percent. This is a 42.38 percent increase over sales of $1.96 billion the same period last year.

APA Q2 Adj $1.17 Beats $1.08 Estimate, Sales $2.79B Beat $2.37B Estimate

Ohio is on the brink of finally opening its recreational cannabis market as 34 medical cannabis businesses, including growers, processors and testing labs have been granted permissions to expand into adult-use sales. This development marks a crucial step towards the state&#8217;s recreational <a href="http://benzinga.com/cannabis">cannabis</a> sales rollout nearly nine months after <a href="https://www.benzinga.com/markets/cannabis/23/11/35664155/ohio-legalizes-cannabis-and-overwhelmingly-approves-abortion-rights">voters approved recreational use</a>, with businesses poised for a surge in demand.
<h3 class="wp-block-heading">Recreational Dispensary Approvals Still Pending</h3>
However, sales have yet to commence due to pending approvals for dispensaries, <a href="https://www.ideastream.org/show/sound-of-ideas/2024-07-31/ohio-granting-permits-to-companies-for-recreational-marijuana-market">according</a> to Ideastream. The Ohio Division of Cannabis Control (DCC) aims to issue dual-use licenses to dispensaries by September 7. Jamie Crawford, a public information officer with the Ohio Department of Commerce, <a href="https://www.benzinga.com/markets/cannabis/24/07/39870999/ohios-adult-use-cannabis-market-takes-its-first-major-step">recently explained that the timing for sales would depend on each dispensary's readiness</a>, emphasizing that the state is ensuring that businesses meet all requirements for a safe and compliant market entry.
<h3 class="wp-block-heading">Key Players In Ohio Ramp Up Production</h3>
Meanwhile, key players like Riviera Creek, Pure Ohio Wellness and Green Thumb Industries Inc (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GTBIF#OTC">GTBIF</a>) have already received dual-use certificates, ramping up production in anticipation of new market demands. This move comes as the <a href="https://www.benzinga.com/markets/cannabis/24/06/39144708/ohio-now-accepting-recreational-marijuana-applications-when-will-sales-begin-official-cant-circl">state processes numerous applications for dual-use operations</a>, reflecting a robust interest in the sector&#8217;s expansion.
Real Also: <a href="https://www.benzinga.com/markets/cannabis/24/07/40045648/kamala-harris-gains-on-trump-in-his-home-state-of-florida-why-cannabis-legalization-and-abortion">Kamala Harris Gains On Trump In His Home State Of Florida: Why? Cannabis Legalization And Abortion Access</a>
<h3 class="wp-block-heading">House Bill 230 Sparks Controversy Over Cannabis Testing</h3>
Amidst these developments, legislative movements are also seeking to shape the landscape. House Bill 230, recently passed in the Ohio House, introduces new measures for addressing drug-related offenses, <a href="https://www.nbc4i.com/news/local-news/central-ohio-news/ohio-bill-would-allow-impaired-driving-test-for-marijuana-but-does-it-work/">reports</a> NBC4, including a controversial provision for oral fluid tests to identify impaired drivers, potentially including those under the influence of cannabis. Critics, including Dennis Cauchon of Harm Reduction Ohio, argue that these tests are not reliably indicative of impairment. &#8220;It sounds good and in certain cases, it makes a difference," Cauchon stated. "But in marijuana oral fluid testing, one isn't better than the other. None of them are very good.&#8221;
This skepticism is echoed in scientific circles, with studies suggesting that <a href="https://www.benzinga.com/markets/cannabis/24/04/38134128/detection-of-cannabis-in-bodily-fluids-not-correlated-with-driving-impairment-new-review-shows">the presence of cannabinoids in saliva or breath does not correlate directly with impairment levels</a>. This raises concerns about the accuracy of such tests, particularly as they risk false positives for people who have consumed non-psychoactive <a href="https://www.benzinga.com/topic/hemp">hemp-derived products</a>.
Ohio's legislative and operational maneuvers aim at setting the stage for a robust adult-use cannabis market <a href="https://www.benzinga.com/markets/cannabis/24/06/39241470/gop-senators-introduce-new-bill-with-changes-to-ohios-cannabis-initiative-as-retail-sales-loom">amid contentious debates on related public safety measures</a>.&nbsp;
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/07/39870999/ohios-adult-use-cannabis-market-takes-its-first-major-step">Ohio&#8217;s Adult-Use Cannabis Market Takes Its First Major Step</a></li>
<li><a href="https://www.benzinga.com/markets/cannabis/24/07/40055095/does-cannabis-affect-your-driving-university-of-colorado-researchers-find-out">Does Cannabis Affect Your Driving? University Of Colorado Researchers Find Out</a></li>
</ul>
Featured image created with AI tools.
<hr class="wp-block-separator has-alpha-channel-opacity" />
Cannabis rescheduling seems to be right around the corner. Want to understand what this means for the future of the industry? Hear directly for top executives, investors and policymakers at the 19th Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9. <a href="https://www.eventbrite.com/e/benzinga-capital-conference-cannabis-fall-2024-tickets-858948065787?aff=oddtdtcreator" target="_blank" rel="noreferrer noopener">Get your tickets now</a> before prices surge by following <a href="https://www.eventbrite.com/e/benzinga-capital-conference-cannabis-fall-2024-tickets-858948065787?aff=oddtdtcreator" target="_blank" rel="noreferrer noopener">this link</a>.

Cannabis

Government

Regulations

GTBIF

Ohio Approves 34 Dispensaries As Recreational Sales Near, New Cannabis DUI Testing Bill Controversy

CTVA

Corteva shares are trading lower after the company reported worse-than-expected Q2 revenue results.  Additionally, the company announced the retirement of CFO Dave Anderson.

Ballys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BALY#NYSE">BALY</a>) reported quarterly losses of $(1.24) per share which beat the analyst consensus estimate of $(1.30) by 4.62 percent. The company reported quarterly sales of $621.657 million which missed the analyst consensus estimate of $639.483 million by 2.79 percent. This is a 2.55 percent increase over sales of $606.206 million the same period last year.

BALY

Ballys Q2 2024 GAAP EPS $(1.24) Beats $(1.30) Estimate, Sales $621.657M Miss $639.483M Estimate

CDNA

CareDx shares are trading higher after the company reported better-than-expected Q2 financial results.

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fpaycom.com%2F&amp;esheet=54102589&amp;newsitemid=20240731673591&amp;lan=en-US&amp;anchor=Paycom+Software%2C+Inc.+%28NYSE%3A+PAYC%29&amp;index=1&amp;md5=7814728bfc633be88caba6b39c33dc61">Paycom Software, Inc. (NYSE:</a><a href="https://www.benzinga.com/stock/PAYC#NYSE">PAYC</a>) ("Paycom"), a leading provider of comprehensive, cloud-based human capital management software, announced today that its board of directors has increased and extended its ongoing stock repurchase plan, such that $1.5 billion is available for repurchases through Aug. 15, 2026. Prior to the increase, approximately $676 million was available for repurchases.

Buybacks

PAYC

Paycom Increases And Extends Stock Repurchase Plan, Such That $1.5B Is Available For Repurchases Through Aug. 15, 2026 (~$676M Was Available For Repurchases)

The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

Comments

VECTION TECH S/ADR by VECTION TECHNOLOGIES LTD

News

Latest news for VECTION TECH S/ADR by VECTION TECHNOLOGIES LTD (OTC:VCTNY) Stock